type 2 diabetes

Showing 15 posts of 46 posts found.

Novo’s Xultophy beats basal insulin in cutting cardiovascular risk

September 14, 2017
Research and Development Novo Nordisk, Xultophy, diabetes, pharma, pharmaceutical, type 2 diabetes

Novo Nordisk has unveiled new data on its diabetes treatment Xultophy (insulin degludec/liraglutide) which supports its efficacy in reducing risk …


Novo diabetes drug outperforms Lilly rival at Phase 3

August 17, 2017
Research and Development Eli Lilly, Novo Nordisk, diabetes, life sciences, medicine, pharma, pharmaceutical, type 2 diabetes

Novo Nordisk has revealed that its diabetes drug semaglutide managed to outperform Eli Lilly’s own treatment dulaglutide (Trulicity) in controlling …


Type 2 diabetes directly linked to BMI

June 12, 2017
Research and Development, Sales and Marketing diabetes, type 2 diabetes

Research emerging from the American Diabetes Association’s meeting in San Diego has revealed that the likelihood of developing type 2 …

NICE recommends Forxiga in Triple Therapy for Diabetes

October 7, 2016
Medical Communications AstraZeneca, Forxiga, NHS, NICE, diabetes, type 2 diabetes

The news of NICE’s approval of the Forxiga comes in a busy week for AstraZeneca. They have sold three drugs, …


Promising results for new type 2 diabetes management procedure

August 12, 2016
Research and Development, Sales and Marketing Fractyl, Revita, diabetes, type 2 diabetes

Fractyl Laboratories has revealed data from its first-in-human study of Revita duodenal mucosal resurfacing (Revita DMR), a new 60-minute, non-surgical …


Novo Nordisk says Victoza lowers risk of heart attacks in diabetes patients

June 14, 2016
Manufacturing and Production, Research and Development Novo Nordisk, Victoza, drug trial, type 2 diabetes

Danish diabetes drugmaker giant Novo Nordisk (NYSE: NVO) on Tuesday said a large study showed its Victoza (liraglutide) reduced the risk of …

Personalised care key to diabetes management, says NICE

December 2, 2015
Research and Development NICE, NICE guidelines, diabetes, type 2 diabetes

UK drugs regulator NICE has published updated guidelines on type 2 diabetes, saying that taking an individualised approach to care …

Jardiance scores more cardiovascular outcomes data

November 10, 2015
Manufacturing and Production Boehringer, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Victoza, cardiovascular outcomes, diabetes, empagliflozin, jardiance, lilly, liraglutide, type 2 diabetes

A sub-group analysis of data from an outcomes study of Boehringer Ingelheim’s and Lilly’s Jardiance has found the diabetes drug …


More positive CV data for Boehringer and Lilly’s Jardiance

September 21, 2015
Research and Development, Sales and Marketing Boehringer Ingelheim, EASD, Eli Lilly, cardiovascular risk, empagliflozin, jardiance, mortality risk, type 2 diabetes

Jardiance, an anti-diabetes drug produced by Boehringer Ingelheim and Eli Lilly, reduces the risk of death in people with type …


Sanofi’s LixiLan meets target in Phase III diabetes trial

September 16, 2015
Research and Development Lantus, LixiLan, Lixisenatide, Lxyumia, Sanofi, diabetes, insulin glargine, metformin, type 2 diabetes

Sanofi’s Phase III clinical trial of its Lixilan treatment has achieved its primary endpoint in patients with type 2 diabetes, …


FDA strengthens safety warning for J&J’s diabetes drug Invokana

September 14, 2015
Sales and Marketing FDA, Food and Drugs Administration, Invokamet, J&J, JJ, Johnson & Johnson, diabetes, invokana, safety warning, type 2 diabetes

Johnson & Johnson has suffered a blow after the FDA strengthened its safety warning for the company’s type 2 diabetes …

google logo

Sanofi joins Google in diabetes tech push

September 1, 2015
Medical Communications Andy Conrad, Google life sciences, Sanofi, Type 1 diabetes, diabetes, google, type 2 diabetes

Google is continuing its work in diabetes, by teaming up with pharma giants Sanofi to create new digital technologies and …


New Boehringer and Lilly type 2 diabetes treatment gets FDA nod

August 28, 2015
Research and Development, Sales and Marketing Boehringer Ingelheim, Eli Lilly, FDA, Synjardy, type 2 diabetes

The FDA has approved Synjardy, from Boehringer Ingelheim and Eli Lilly, for the treatment of adults with type 2 diabetes. …

Novo Nordisk pushes forward with new diabetes drug trial

July 13, 2015
Research and Development GLP-1 agonist, Novo Nordisk, diabetes, phase III, semaglutide, type 2 diabetes

Novo Nordisk is taking the first steps towards adding another type 2 diabetes drug to its portfolio, after announcing positive …

Boehringer and Vitae Pharma drug fails in mid-stage trial

July 1, 2015
Research and Development BI, Boehringer, Boehringer Ingelheim, Vitae Pharmaceuticals, diabetes, type 2 diabetes

A pipeline diabetes drug co-developed by Vitae Pharma and German giants Boehringer Ingelheim has failed to show benefits in a …

Latest content